Compare Carvana Co (CVNA) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Novartis AG — how do they compare? Carvana Co trades at $63.77 (market cap $69.55B), while Novartis AG trades at $142.86 (market cap $268.57B). The key difference: Novartis AG is far larger — about 3.9× Carvana Co's market cap, and Novartis AG pays a 3.31% dividend while Carvana Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Novartis AG for 82 Days on average.
| CVNA | NVS | |
|---|---|---|
Market Cap | $69.55B | $268.57B |
Volume | 7,671,750 | 1,532,573 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $168.62 |
52-Week Low | $56.27 | $121.80 |
Typical Hold Time | 28 Days | 82 Days |
Enterprise Value | $72.04B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $62.76, down 1.72% on the day, amid a bearish technical signal despite strong fundamental performance. The company reported robust revenue growth, with 2025 revenue reaching $20.32B and net income of $1.41B, and has consistently beaten EPS estimates in recent quarters. Analyst consensus is mixed with a $84.07 price target, while technical indicators show resistance near $64 and support at $61.
Outlook remains cautiously optimistic given operational strength and growth trajectory, but high debt levels and competitive pressures pose risks. The stock offers upside if execution continues, yet volatility and macroeconomic factors warrant careful monitoring for investors.
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
